Brief: Dermapharm H1 EBITDA At EUR 148.7 Mln, Up 8.5% Y/Y

Dermapharm Holding SE

07/09/2022 07:05

Sept 7 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * DERMAPHARM HOLDING SE PUBLISHES H1 2022 FINANCIAL REPORT,
CONFIRMS OUTLOOK FOR 2022 OVERALL
    * H1 EBITDA ROSE 8.5 PERCENT TO 148.7 MILLION EUR
    * OUTLOOK FOR 2022 CONFIRMED
    * H1 ADJUSTED CONSOLIDATED EBITDA MARGIN: 31.6%
    * H1 ADJUSTED CONSOLIDATED EBITDA GREW BY 8.5% TO EUR 148.7
MILLION
    * H1 CONSOLIDATED REVENUE UP YEAR ON YEAR BY 10.1% TO EUR
471.1
MILLION
    * HILDE NEUMEYER WILL BE SUCCEEDED AS CHIEF FINANCIAL
OFFICER BY
CHRISTOF DREIBHOLZ ON 1 NOVEMBER 2022

Source text for Eikon:  ID:nEQ253FZla 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))